Form 4: Dexcom Director Mark G. Foletta Sells Shares Under 10b5-1 Plan

Director Mark G. Foletta sold Dexcom Inc. shares on June 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark G. Foletta, a director of Dexcom Inc., executed multiple sales of common stock on June 17 and 18, 2024.
• The sales were conducted under a 10b5-1 trading plan adopted by the Foletta Family Trust on March 15, 2024.
• On June 17, 2024, a total of 2,694 shares were sold at weighted average prices of $115.18, $117.1607, and $117.7717.
• On June 18, 2024, a total of 3,306 shares were sold at weighted average prices of $116.7493 and $117.2455.
• Following these transactions, the Foletta Family Trust continues to beneficially own 56,398 shares of Dexcom Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as the sales were conducted under a pre-arranged 10b5-1 plan.

Industry Context

Insider sales are a common occurrence and are often viewed in the context of pre-planned trading activities, such as those under a 10b5-1 plan. It's important to consider the overall trend of insider transactions and the company's performance when evaluating the significance of these sales.

Comparison to Industry Standards

• Comparing Foletta's transactions to other directors in similar medical device companies like Medtronic (MDT) or Abbott Laboratories (ABT) could provide context.
• Analyzing the percentage of shares sold relative to total holdings is a standard practice.
• Reviewing the timing of these sales in relation to Dexcom's earnings announcements or product releases is also relevant.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates